Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Canter

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
BJU International|June 22, 2010
Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapyDaniel Canter, Christopher Long, Alexander Kutikov, et al.
Urology|August 17, 2010
Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomyDaniel Canter, Rosalia Viterbo, Alexander Kutikov, et al.
The Journal of Urology|May 20, 2014
Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancerJeffrey J Tomaszewski, Elizabeth Handorf, Anthony T Corcoran, et al.
Urology|July 5, 2011
Clinical Stage T1 micropapillary urothelial carcinoma presenting with metastasis to the pancreasDaniel Canter, Jay Simhan, Marc C Smaldone, et al.
Urologic Oncology|June 11, 2014
Patients with anatomically "simple" renal masses are more likely to be placed on active surveillance than those with anatomically "complex" lesionsJeffrey J Tomaszewski, Robert G Uzzo, Neil Kocher, et al.
The Canadian Journal of Urology|June 21, 2013
Is there a benefit to frozen section analysis at the time of partial nephrectomy?Steven N Sterious, Jay Simhan, Marc C Smaldone, et al.
European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.
Oncotarget|September 18, 2018
A patient-derived orthotopic xenograft model enabling human high-grade urothelial cell carcinoma of the bladder tumor implantation, growth, angiogenesis, and metastasisJessie Gills, Ravan Moret, Xin Zhang, et al.
The Journal of Urology|June 18, 2016
Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant ChemotherapyWilhelmina C M Duivenvoorden, Siamak Daneshmand, Daniel Canter, et al.
The Journal of Urology|May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 TrialVikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
BJU International|June 22, 2010
Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapyDaniel Canter, Christopher Long, Alexander Kutikov, et al.
Urology|August 17, 2010
Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomyDaniel Canter, Rosalia Viterbo, Alexander Kutikov, et al.
The Journal of Urology|May 20, 2014
Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancerJeffrey J Tomaszewski, Elizabeth Handorf, Anthony T Corcoran, et al.
Urology|July 5, 2011
Clinical Stage T1 micropapillary urothelial carcinoma presenting with metastasis to the pancreasDaniel Canter, Jay Simhan, Marc C Smaldone, et al.
Urologic Oncology|June 11, 2014
Patients with anatomically "simple" renal masses are more likely to be placed on active surveillance than those with anatomically "complex" lesionsJeffrey J Tomaszewski, Robert G Uzzo, Neil Kocher, et al.
The Canadian Journal of Urology|June 21, 2013
Is there a benefit to frozen section analysis at the time of partial nephrectomy?Steven N Sterious, Jay Simhan, Marc C Smaldone, et al.
European Urology|January 30, 2025
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 TrialJohann S de Bono, Meng He, Zhen Shi, et al.
Oncotarget|September 18, 2018
A patient-derived orthotopic xenograft model enabling human high-grade urothelial cell carcinoma of the bladder tumor implantation, growth, angiogenesis, and metastasisJessie Gills, Ravan Moret, Xin Zhang, et al.
The Journal of Urology|June 18, 2016
Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant ChemotherapyWilhelmina C M Duivenvoorden, Siamak Daneshmand, Daniel Canter, et al.
The Journal of Urology|May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 TrialVikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
Pageof 6